Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Medicines licensing

FDA approves drug for dry eye disease

A new class of drug is being made available in the United States to treat the signs and symptoms of dry eye disease, the US Food and Drug Administration (FDA) has announced.

The FDA, which governs medicines safety, has approved the use of lifitegrast ophthalmic solution, branded as Xiidra by Shire US. Lifitegrast is a lymphocyte function-associated antigen 1 (LFA-1) agonist.

The decision was based on the results of four separate randomised controlled trials involving more than 1,000 patients, in which participants were randomised equally to receive either lifitegrast or placebo eye drops, administered twice a day for 12 weeks. Patients treated with lifitegrast showed greater improvement in both the signs and the symptoms of eye dryness compared with patients in the placebo group.

The most commonly reported side effects of the new drug include eye irritation, discomfort or blurred vision and an unusual taste sensation.

Dry eye disease occurs when the eye fails to produce an adequate volume of tears or when the tears are not of the correct consistency. If severe and left untreated, the condition can lead to pain, ulcers or scars in the cornea. Symptoms can make it more difficult to use a computer or read for a long time and can make dry environments, such as the inside of an airplane, more uncomfortable.

Incidence of dry eye disease increases with age; it does not routinely appear in children aged under 17 years.

Shire expects to launch Xiidra in the United States in the third quarter of 2016.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2016.20201426

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

  • Drugs of Abuse

    Drugs of Abuse

    A concise, easy-to-read guide for healthcare professionals who encounter drug abuse.

    £38.00Buy now
  • Adverse Drug Reactions

    Adverse Drug Reactions

    A practical guide to the drug reactions that affect particular organ systems, and the management of these reactions.

    £38.00Buy now
  • English Delftware Drug Jars

    English Delftware Drug Jars

    This beautiful book illustrates the art and history of the collection of English delftware drug jars in the Museum of the Royal Pharmaceutical Society of Great Britain.

    £54.00Buy now
  • Paediatric Drug Handling

    Paediatric Drug Handling

    Written for new pharmaceutical scientists, this book provides a background in paediatric pharmacy and a comprehensive introduction to children's medication.

    £33.00Buy now
  • Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics

    Introduction to Renal Therapeutics covers all aspects of drug use in renal failure. Shows the role of the pharmacist in patient care for chronic kidney disease.

    £38.00Buy now

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • Close up image of an eye

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.